Movement Alert｜Stryker Intraday Rise 3.01% in Regular Trading, FDA Clears Sonopet 3 Tissue Resection Platform

Market Focus10-15 22:14

On October 15, Stryker rose 3.01% in Regular Trading, trading near $290.23 per share, with turnover of $144 million.

The move followed the company’s disclosure that its Sonopet 3 ultrasonic bone and soft tissue resection platform received FDA 510 clearance, with initial clinical cases expected to begin in October and broader commercialization planned later in the fall.

The clearance adds to recent momentum in Stryker’s surgical and neurotechnology portfolio expansion. Earlier in the year, the company also reported second-quarter adjusted EPS of $3.69 on revenue of $6.59 billion, both ahead of expectations, and lifted its full-year adjusted EPS outlook to $14.95-$15.10, providing supportive operating context alongside the latest product approval.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment